Founded in 2023, TECregen develops biologics aimed at regenerating the thymus to restore immune function. The CHF 10 million seed round will fund the advancement of its candidates towards the clinic.
- Announced on
- Round
- Seed
- Amount
- CHF 10 M
- Location
- Basel, canton of Basel-Stadt
- Sector
- Biotech & life sciences
Investors
- Boehringer Ingelheim Venture Fund (BIVF) lead
- LifeSpan Vision Ventures
- Carma Fund
- EOS BioInnovation
- High-Tech Gründerfonds
- JFG Life Sciences Foundation
- Zurich Cantonal Bank
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic